Suppr超能文献

高C反应蛋白与淋巴细胞比值可预测HBV相关失代偿期肝硬化的不良预后。

High C-Reactive Protein-to-Lymphocyte Ratio Is Predictive of Unfavorable Prognosis in HBV-Associated Decompensated Cirrhosis.

作者信息

Ye Bin, Ding QiuMing, He Xia, Liu XiaoYun, Shen Jianjiang

机构信息

Department of Critical Care Medicine, Shengzhou People's Hospital, Shengzhou Branch of the First Affiliated Hospital of Zhejiang University, Shengzhou, China.

Department of Clinical Laboratory, Shengzhou People's Hospital, Shengzhou Branch of the First Affiliated Hospital of Zhejiang University, Shengzhou, China.

出版信息

Lab Med. 2022 Nov 3;53(6):e149-e153. doi: 10.1093/labmed/lmac019.

Abstract

OBJECTIVE

Hepatitis B virus-associated decompensated cirrhosis (HBV-DeCi) is difficult to cure and has a very high risk of mortality. However, prediction of its prognosis is challenging. The C-reactive protein-to-lymphocyte ratio (CLR) is a newly discovered inflammatory indicator, but its role in HBV-DeCi remains unclear. In the present study, we sought to determine the prognostic role of the CLR in patients with HBV-DeCi.

MATERIALS AND METHODS

This retrospective study enrolled 134 patients with HBV-DeCi. Independent prognostic markers were identified using multivariate regression analysis.

RESULTS

The 30-day mortality rate was 12.7% (n = 17). The CLR was markedly higher in nonsurvivors compared with survivors. The multivariate analysis identified a high CLR as an independent risk factor for mortality.

CONCLUSION

We found that the CLR is an effective and simple prognostic marker in patients with HBV-DeCi.

摘要

目的

乙型肝炎病毒相关性失代偿期肝硬化(HBV-DeCi)难以治愈,死亡率极高。然而,预测其预后具有挑战性。C反应蛋白与淋巴细胞比值(CLR)是新发现的炎症指标,但其在HBV-DeCi中的作用尚不清楚。在本研究中,我们试图确定CLR在HBV-DeCi患者中的预后作用。

材料与方法

本回顾性研究纳入了134例HBV-DeCi患者。采用多因素回归分析确定独立的预后标志物。

结果

30天死亡率为12.7%(n = 17)。与存活者相比,非存活者的CLR明显更高。多因素分析确定高CLR是死亡的独立危险因素。

结论

我们发现CLR是HBV-DeCi患者有效且简单的预后标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验